Sign In
Buy AMRX
$12.88
+0.225 (+1.78%)
At Close: Jun 03, 2026
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10:41am, Thursday, 02'nd Oct 2025
Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
3 Lesser-Known Healthcare Names With Major Upside in Store
08:19am, Thursday, 02'nd Oct 2025
The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current ma
Amneal to Report Third Quarter 2025 Results on October 30, 2025
04:05pm, Tuesday, 30'th Sep 2025
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Comp
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
08:00am, Friday, 26'th Sep 2025
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
08:00am, Tuesday, 23'rd Sep 2025
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
08:00am, Thursday, 11'th Sep 2025
BRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal's s
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing
07:23am, Thursday, 11'th Sep 2025
For my initial rating of Amneal Pharmaceuticals (AMRX), I am calling it a buy. I was impressed by its large, diversified portfolio of therapies across clinical segments, and active pipeline of future
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
04:01pm, Thursday, 04'th Sep 2025
BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperido
Wall Street Analysts Think Amneal (AMRX) Could Surge 25.52%: Read This Before Placing a Bet
10:56am, Monday, 01'st Sep 2025
The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Wall Street Analysts See a 27.66% Upside in Amneal (AMRX): Can the Stock Really Move This High?
10:56am, Thursday, 14'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv
Here's Why Momentum in Amneal (AMRX) Should Keep going
09:51am, Wednesday, 13'th Aug 2025
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
Amneal (AMRX) Q2 EPS Jumps 56%
04:39pm, Tuesday, 05'th Aug 2025
Amneal (AMRX) Q2 EPS Jumps 56%
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript
02:56pm, Tuesday, 05'th Aug 2025
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investo
Amneal (AMRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Tuesday, 05'th Aug 2025
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to
Amneal Pharmaceuticals (AMRX) Q2 Earnings Top Estimates
08:15am, Tuesday, 05'th Aug 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.
